Skip to main content

Tenants

Sonoval

Sonoval is developing novel anticancer therapies for lymphomas and solid tumors that work in two ways:

  1. Destroying cancers by binding to receptors on tumor cells and delivering a toxic payload.
  2. Eliminating immune system suppressors, unleashing the patient's own anticancer defenses.

Sonoval's protein-based anticancer drug candidates, including SON-211 and others, are each engineered to minimize potential side-effects and are manufactured using proprietary expression technology.

Contact Name: 
Peter Suzdak, PhD
Chief Executive Officer
Address: 
801 W. Baltimore St.
Suite 502L
Baltimore  Maryland  21201
United States
Email: 
Website: